Novel Arylimidamides for Treatment of Visceral Leishmaniasis

Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC(50)], <1 μM) against both Leishmania donovani axenic amastigotes and intracellular Leishmania, the causative agent for human visceral leishmaniasis (VL). A syste...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang, Michael Zhuo, Zhu, Xiaohua, Srivastava, Anuradha, Liu, Qiang, Sweat, J. Mark, Pandharkar, Trupti, Stephens, Chad E., Riccio, Ed, Parman, Toufan, Munde, Manoj, Mandal, Swati, Madhubala, Rentala, Tidwell, Richard R., Wilson, W. David, Boykin, David W., Hall, James Edwin, Kyle, Dennis E., Werbovetz, Karl A.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology (ASM) 2010
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876428/
https://ncbi.nlm.nih.gov/pubmed/20368397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00250-10
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires